WO2003053471A1 - Aqueous sustained-release formulations of proteins - Google Patents
Aqueous sustained-release formulations of proteins Download PDFInfo
- Publication number
- WO2003053471A1 WO2003053471A1 PCT/US2002/036300 US0236300W WO03053471A1 WO 2003053471 A1 WO2003053471 A1 WO 2003053471A1 US 0236300 W US0236300 W US 0236300W WO 03053471 A1 WO03053471 A1 WO 03053471A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- factor
- erythropoietin
- cmc
- weeks
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Definitions
- the present invention provides aqueous sustained-release pharmaceutical formulations of therapeutic proteins containing carboxymethyl ether cellulose polymer and their method of manufacture.
- the present invention also provides methods to use the pharmaceutical formulations that provide a variety of new benefits, including greater efficacy, safety, patient convenience, and patient compliance.
- proteins known to exhibit various pharmacological actions in vivo are capable of production in large amounts for pharmaceutical applications.
- a major limitation of the development of protein therapeutics is the preparation of stable pharmaceutical formulations of the proteins.
- Therapeutic proteins are typically administered by frequent injection because the active agent protein generally has short in vivo half-lives and negligible oral bio-availability, thus posing a significant physical burden on the patient and associated administrative costs. As such, there is currently a great deal of interest in developing and evaluating sustained-release formulations. Effective sustained-release formulations can provide a means of controlling blood levels of the active ingredient, and also provide greater efficacy, safety, patient convenience and patient compliance.
- sustained-release formulations of protein encapsulated in polymer microspheres.
- the advantage to generating sustained release formulations is that the formulation could theoretically be utilized for many protein therapeutics.
- PCT publication WO 00/38651 describes a pharmaceutical composition containing a protein in a polymeric matrix that has thermally and pH responsive gelation/de-gelation properties. These formulations may be prepared without exposure to heat or organic solvents, but are characterized by their use of modified hydrogels.
- the use of thermostable hydrogels suffers by undesirable difficulties of manufacture and thus is currently commercially impractical.
- Another undesirable characteristic of these modified hydrogels is that their biocompatibility or immunogenicity is poorly characterized.
- the present invention provides a method to prepare aqueous sustained-release pharmaceutical formulations of therapeutic proteins for parenteral administration.
- the present invention also provides pharmaceutical formulations for general use with proteins for parenteral administration comprising: a) a pharmaceutically active amount of a protein; b) a pharmaceutically acceptable pH buffering agent to provide a pH in the range of about pH 4.5 to about pH 9; c) a tonicity agent in the concentration range of about 0 to about 125 millimolar; and d) Sodium carboxymethyl ether cellulose in the concentration range of about 0.5% to about 7% total formula weight; wherein the pH of the aqueous formula is about 4.5 to about pH 9.0.
- a preferred formulation of the present invention provides a pharmaceutical formulation of erythropoietin comprising: a) a pharmaceutically active amount of erythropoietin; b) a pharmaceutically acceptable pH buffering agent to provide a pH in the range of about pH 6 to about pH 9; c) a tonicity agent in the concentration range of about 0 to about 200 millimolar; and d) sodium carboxymethyl ether cellulose (CMC) in the concentration range of about 0.5% to about 7% total formula weight, said CMC having a molecular Ortl531
- the present invention also provides a method to prepare aqueous sustained-release pharmaceutical formulations of erythropoietin comprising admixing an aqueous solution of a CMC polymer with a pharmaceutically active amount of EPO.
- the formulations of the present invention utilize CMC polymer that is primarily in a solution state rather than in a micro-particulate state.
- the present invention also provides methods to use these sustained-release formulations comprising dosing regimens where the formulation is administered at a wide variety of desired intervals, including, but not limited to, thrice per two weeks, once per week, once per two weeks, once per three weeks, once monthly, once per five weeks, once per six weeks, or at any other time interval or combination of time intervals that may be desirable for the particular patient.
- FIG. 1 Pharmacokinetics of sustamed-release formulations CMC-1, CMC-2, CMC- 3, CMC-4 illustrated as mean Plasma Epogen Alfa concentration versus time.
- FIG. 1 Pharmacodynamics of sustained-release formulations CMC-1, CMC-2,
- CMC-3, CMC-4 illustrated as change in the percentage reticulocytes versus time.
- FIG. 1 Pharmacodynamics of sustained-release formulations CMC-1, CMC-2,
- CMC-3, CMC-4 illustrated as change in the amount of Hemoglobin versus time.
- CMC-3, CMC-4 illustrated as change in the number of red blood cells versus time.
- Figure 5 Pharmacokinetics of Clinical Batch CMC-EPO illustrated as mean Plasma Epoetin Alfa concentration versus time.
- Figure 6 Pharmacodynamics of Clinical Batch CMC-EPO illustrated as change in the percentage of reticulocytes versus time.
- Figure 7 Pharmacodynamics of Clinical Batch CMC-EPO illustrated as change in the amount of Hemoglobin versus time.
- Figure 8 Pharmacodynamics of Clinical Batch CMC-EPO illustrated as change in the number of red blood cells versus time.
- erythropoietin or "EPO” shall include those polypeptides and proteins that have the biological activity of recombinant human erythropoietin (rhEPO), as well as erythropoietin analogs, erythropoietin isoforms, erythropoietin mimetics, erythropoietin fragments, hybrid erythropoietin proteins, fusion proteins oligomers and multimers of the above, homologues of the above, glycosylation pattern variants of the above, and muteins of the above, regardless of the biological activity of same, and further regardless of the method of synthesis or manufacture thereof including, but not limited to, recombinant (whether produced from cDNA or genomic DNA), synthetic, transgenic, and gene activated methods.
- erythropoietin include, Epoetin alfa (EPREX ® ,
- ERYPO ® PROCRIT ®
- novel erythropoiesis stimulating protein SEBpoetin alfa
- Epoetin the hyperglycosylated analog of recombinant human erythropoietin (Epoetin) described in European patent application EP640619, human erythropoietin analog (such as the human serum albumin fusion proteins described in the international patent application WO9966054), erythropoietin mutants described in the Ortl531
- erythropoietin omega which may be produced from an Apa I restriction fragment of the human erythropoietin gene described in United States patent 5,688,679, altered glycosylated human erythropoietin described in the international patent application WO9911781 and EP1064951, PEG conjugated erythropoietin analogs described in WO9805363 or United States patent 5,643,575.
- EPO erythropoietin
- rhEPO purified recombinant human EPO
- EPREX ® ERYPO ®
- PROCRIT ® PROCRIT ®
- ARANESPTM ARANESPTM
- protein includes peptides, polypeptides, consensus molecules, analogs, derivatives or combinations thereof.
- protein embraces polypeptide sequences containing modified amino acids and glycoproteins, or proteins that contain at least one serine, threonine, or arginine side chain bearing a carbohydrate moiety. Also included are those polypeptides with amino acid substitutions that are "conservative" according to acidity, charge, hydrophobicity, polarity, size or any other characteristic known to those skilled in the art. See generally, Creighton, Proteins. W.H. Freeman and Company, NY (1984) pp. 498.
- Small amino terminal extensions such as an amino-terminal methionine or serine residue, a small linker peptide of up to about twenty to twenty-five residues, or a small extension that facilitates purification, such as a poly-histidine tract, an antigenic epitope or a binding domain, may also be present. See, in general, Ford et al., Protein Expression and Purification (1991) 2:95-107. Polypeptides or analogs thereof may also contain one or more amino acid analogs, such as peptidomimetics. One skilled in the art will readily be able to adapt a desired protein active agent to the compositions of present invention.
- subject refers to an animal, preferably a mammal, most preferably a human, who is the object of treatment, observation or experiment.
- the amount of protein used in the formulations of the present invention will vary with the biological potency of the protein as well as the desired potency of the formulation, but will generally contain about 1 ⁇ g/ml to about 2000 ⁇ g/ml protein per formulation.
- the erythropoietin-containing formulations o£ the present, invention nay .contain a "pharmaceutically active amount of erythropoietin", generally about 1000 IU/ml to about 180,000 IU/ml of erythropoietin, wherein 120,000 IU is approximately 1000 ⁇ g.
- the erythropoietin may be provided as an aqueous solution of a bulk reagent that is diluted into the formulation of the present invention or may be provided as a dried reagent and reconstituted using the appropriate amount of the aqueous formulation.
- Dried reagents include, for example, lyophilized or spray-dried erythropoietin.
- erythropoietin is provided as a bulk reagent in formulations of high potency (e.g. greater than 100,000 IU/ml), it is preferable that the erythropoietin bulk reagent be provided in a phosphate buffered solution.
- Buffer exchange is achieved using methods well known in the art, such as diaftltration or dialysis to provide an EPO bulk that contains less than 1 millimolar citrate.
- the amount of buffering agent useful in the pharmaceutical compositions of the present invention depends largely on the particular buffer used and the desired pH of the formulation.
- the concentration of buffering ions will generally range from about 10 mM to about 30 mM.
- Suitable buffer systems to maintain the pH range of about four to about nine include, but are not limited to, sodium citrate/citric acid, sodium acetate/acetic acid, sodium or potassium phosphate dibasic/monobasic, and any other pharmaceutically acceptable pH buffering agent(s) known in the art.
- the use of a buffer system of sodium phosphate dibasic and sodium phosphate monobasic is preferred.
- a pH-adjusting agent such as, but not limited to, hydrochloric acid, citric acid, sodium hydroxide, or a salt of any of these, in particular sodium citrate, may be added to the formulations to adjust the Ortl531
- phosphate buffer systems are particularly preferred in all formulations of the present invention, both in the aqueous protein bulk reagent and in the formulation buffer component.
- the preferred pH range for the protein-containing formulations of the present invention is between about pH 4.5 to about pH 9, preferably in the range of about pH 6 to about pH 7.5.
- the preferred pH range for the erythropoietin-containing formulations of the present invention is between about pH 6.5 to about pH 8, preferably in the range of about pH 6.9 to about pH 7.4.
- One or more ionic tonicity agents may be used in the formulations of the present invention.
- An ionic tonicity agent is any agent capable of rendering the formulations of the present invention iso-osmotic or nearly iso-osmotic with human blood and carries a positive or negative charge in aqueous solutions.
- suitable tonicity agents are well known in the art, and include but are not limited to sodium chloride, potassium chloride, ammonium sulfate, glycine, or other amino acids.
- the preferred tonicity agents of the present invention include, but are not limited to, NaCl, KC1, and glycine, said agent being used at a concentration in the range of about 0 to about 170 millimolar.
- sodium chloride as a tonicity agent is preferred in the formulations of the present invention at a concentration of about 75mM to about lOOmM.
- the type of tonicity agent and its concentration may influence the sustained-release properties of the formulation.
- the total concentration of tonicity agents is generally less than 200 mM.
- CMC Sodium carboxymethyl ether cellulose having a molecular weight of about 50,000 to 1,000,000 is used in the formulations of the present invention in the concentration range of 0.5% to about 7% total formula weight, preferably from about 0.5% to about 2%, and most preferably at about 2%.
- concentration of CMC used is OH1531
- the sustained-release activity of the formulation is tested by comparing pharmacokinetic properties of a CMC containing formulation to an otherwise identical formulation lacking CMC.
- Formulations containing 0.5% to about 2% CMC are generally preferred due to their ease ofmanufacture and because of the ease of administration by injection. .
- the amount of protein/CMC may be expressed as a ratio of protein (in micrograms) to % CMC (grams per 100 mL).
- Preferred formulations of EPO contain a ratio less than or equal to 660 ⁇ g EPO/% CMC.
- sustained release refers to beneficial pharmacokinetic properties of the formulation.
- Pharmacokinetic parameters may be calculated using methods known in the art or as described herein. For example, but not by way of limitation, one or more pharmacokinetic parameters may be calculated by model independent methods using WinNonlin software, Version 1.1 (Scientific Consulting, Incorporation, Apex, NC).
- Various pharmacokinetic properties may be considered when evaluating the sustained-release properties of a formulation of the present invention. For example, but not by way of limitation, the following PK parameters may be evaluated to determine the sustained-release properties of the formulations of the present invention:
- Peak serum concentration (Cr y) The observed maximum serum concentration of the protein.
- a sustained-release formulation may have a lower C raax than a similar non-sustained release formulation due to slower absorption into circulation.
- a sustained-release formulation may have a longer T max than a similar non-sustained release formulation due to slower diffusion into circulation.
- Terminal half-life (t ) A sustained release formulation may have a longer t ⁇ /2 than a similar non-sustained release formulation.
- both the protein and the CMC carry a negative charge, and thus another component, possibly the charged tonicity agent, forms an "ionic bridge", similar to a salt- bridge as is well-known in biochemical interactions.
- the CMC and/or the ionic tonicity agent is sufficiently strong to retard diffusion of the protein from the injection site without being permanently retained at the site. It is readily apparent to those of ordinary skill iri the art that the formulations of the present invention are generally applicable to parenteral administration of therapeutic proteins other than erythropoietin, including, but not limited to, interferons, granulocyte colony stimulating factor, insulin, antibodies and antibody fragments, somatotropin, tissue plasminogen activator, interleukins, and antigens for immune responses.
- the formulations of the present invention utilize CMC polymer that is primarily in a solution state rather than in a micro-particulate state, however a wide variety of ratios of micro-particulate CMC polymer to non-microparticulate CMC polymer may be suitable for use in the formulations of the present invention.
- Proteins and polypeptides suitable for use in the present invention include, but are not limited to, insulin, motilin, gastrin, prolactin, adrenocorticotropic hormone (ACTH), erythropoietin, growth hormone (GH), kerantinocyte growth factor (KGF), stem cell factor
- SCF thrombopoietin
- OPG osteoprotegerin
- OB protein protein may also be referred to herein as leptin
- G-CSF granulocyte colony-stimulating factor
- alpha interferon in particular alpha 2b
- beta interferon in particular beta la and beta lb
- gamma interferon interleukin 2
- FGF fibroblast growth factors
- IGFs insulin-like growth factors
- M-CSF macrophage colony stimulating factor
- GM-CSF granulocyte macrophage colony stimulating factor
- CSFs colony simulating growth factors
- necrosis factor TNF
- TNF thyroid stimulating hormone
- LH luteinizing hormone
- FSH follicle stimulating hormone
- HCG human chorionic gonadotropin
- NGF neurotrophic growth factor
- NT3 neurotrophic factor 3
- NT4 neurotrophic factor 4
- BDNF brain- derived neurotrophic factor
- GDNF glial cell line derived neurotrophic factor
- PGDF platelet-derived growth factor
- TNF necrosis factor
- TNF thyroid stimulating hormone
- LH luteinizing hormone
- FSH human chorionic gonadotropin
- NGF neurotrophic growth factor
- GDNF neurotrophic factor 3
- NT4 neurotrophic factor 4
- BDNF brain- derived neurotrophic factor
- GDNF glial cell line derived neurotrophic factor
- PGDF platelet-derived growth factor
- TAA tissue plasminogen activator
- urokinase streptokinase
- the formulations of the present invention are prepared by admixing the formulation reagents in an aqueous solution such that the components are mixed substantially uniformly so that none of the components are localized.
- Advantageously all of the formulation components, except the protein component, can be prepared and adjusted to conditions suitable for the protein prior to the addition of the protein component.
- the protein bulk reagent may be diafiltered into an appropriate buffer system, preferably phosphate buffer, and the other reagents may be added to the protein bulk, and the bulk protein concentration can be adjusted appropriately to the desired potency.
- a preferred method of formulation for erythropoietin-containing formulations of the present invention, as well as other protein-containing formulations generally, comprises the steps: a) difiltering a recombinant human EPO bulk solution against a 10 to 30 millimolar phosphate buffer to provide a phosphate buffered EPO bulk containing less than ImM citric acid; b) admixing a quantity of CMC to the phosphate buffered EPO bulk Ortl531
- the formulations of the present invention are administered to a subject in need thereof via parental administration excluding intravenous administration.
- routes of parenteral administration include, but are not limited to, intramuscular, subcutaneous, intraperitoneal, intracerebral, intraventricular, intracerebroventricular, intrathecal, intracisternal, intraspinal and/or peri-spinal routes of administration by delivery via intracranial or intravertebral needles and/or catheters with or without pump devices.
- the route of administration may be selected based on the therapeutic indication of the pharmaceutically active protein.
- OB protein may also be referred to herein as leptin), granulocyte colony-stimulating factor (G-CSF), alpha interferon (in particular alpha 2b), beta interferon (in particular beta la and beta lb), gamma interferon, interleukin 2, insulin-like growth factors (IGFs), macrophage colony stimulating factor (M-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), colony simulating growth factors (CSFs), tumor necrosis factor (TNF), thyroid stimulating hormone (TSH), luteinizing hormone (LH),
- IGFs insulin-like growth factors
- M-CSF macrophage colony stimulating factor
- GM-CSF granulocyte macrophage colony stimulating factor
- CSFs colony simulating growth factors
- TNF thyroid stimulating hormone
- TNF thyroid stimulating hormone
- LH luteinizing hormone
- interleukin- 1 receptor antagonist IL-Ira
- REMICADE REMICADE
- ENBREL may be administered via intramuscular, subcutaneous, or intraperitoneal routes such that there is a systemic release of the protein.
- Certain -growth factors such as kerantinocyte growth factor (KGF), fibroblast growth factors (FGF), platelet-derived growth factor (PGDF: also known as interleukin 11), may be administered at or near a site of action to achieve a localize benefit.
- Local injection of the formulation of the present invention may result in higher local-area concentrations of the active pharmaceutical reagent and may be more efficacious than topical administration of medicinal gels containing these proteins.
- Neurologically active proteins including erythropoietin (EPO), neurotrophic growth factor (NGF), neurotrophic factor 3 (NT3), neurotrophic factor 4 (NT4), brain-derived neurotrophic factor (BDNF), glial cell line derived neurotrophic factor (GDNF), bone morphogenetic protein (BMP) may be administered directly into neuronal tissue by intracerebral, intraventricular, intracerebroventricular, intrathecal, intracisternal, intraspinal and/or peri-spinal routes of administration by delivery via intracranial or intravertebral needles and/or catheters with or without pump devices.
- EPO erythropoietin
- NEF neurotrophic growth factor
- NT3 neurotrophic factor 3
- NT4 neurotrophic factor 4
- BDNF brain-derived neurotrophic factor
- GDNF glial cell line derived neurotrophic factor
- BMP bone morphogenetic protein
- the phrase "therapeutically effective” is generally from about 1 to 10000 I.U./kg, preferably from about 50 to 2000 I.UVkg, more preferably from about 50 to 600 I.U./kg, and most preferably from about 50 to 300 I.U/kg body weight especially when erythropoietin is administered subcutaneously.
- the formulations of the present invention may be administered to a responding subject at any desired frequency or time interval between administrations without reduced efficacy.
- the subject is administered the sustained release formulations of the present invention thrice per two weeks, once per week, once per two weeks, once per three weeks, once per month, once per five weeks, once per six weeks, or at more frequent or less frequent intervals, or at any combination of frequencies or time intervals as desired.
- the effective daily dosing of erythropoietin (EPO) is preferably from about 4000 to about 9000 Ortl531
- EPO erythropoietin
- a preferred dosing regimen may be once per three weeks, particularly for subjects receiving chemotherapy for the treatment of cancer, since many chemotherapeutic regimens are administered on a once per three-week schedule.
- any dosing schedule of a therapeutic protein, such as EPO, formulated according to the present invention can be easily coordinated with regular visits to the treating physician or with the dosing schedule of another agent, such as an anti-tumor agent, as is desirable for the patient. This allows the EPO regimen and the chemotherapeutic regimen to be administered simultaneously or in parallel, providing an economic and desirable benefit for the subject.
- EPO administration is delayed or withheld if the patient, male or female, exhibits a hemoglobin level in excess of about 18 g/dL for a human male and about 16 g/dL for a human female.
- the following examples are provided for the purpose of illustrating the present invention, without, however, limiting the present invention to the illustrative examples.
- EPO erythropoietin
- CMC 1 15,000 IU EPO, 0.5% CMC, 10 mM NaPhosphate buffer, pH 7,
- EPO formulations were stored refrigerated ( ⁇ 4 °C) protected from light when not used on study.
- Dogs were group housed in a dog holding room and acclimated to handling and sample collection prior to dose administration. Quarantine was held at least five days prior to dose administration. At the end of the quarantine period, the health of all animals was Ortl531
- Animal rooms were maintained at 23 ⁇ 3 °C with a relative humidity of 50 ⁇ 15% and a twelve-hour light/dark cycle. There were at least ten room air changes per hour.
- Test and control formulations were administered to the dogs on Day 1 (all formulations administered at the volume specified in the following table). The dose was drawn-up into a syringe fitted with appropriate gauge needle. The subcutaneous dose was administered in the dorsal neck region. Dose sites were clipped prior to dosing and marked with indelible ink.
- Plasma will be frozen at -20 °C until analysis.
- Vacutainer® containing EDTA was obtained in the morning and placed on ice. The secondary collection was stored at approximately 4 °C as whole blood and used for reticulocyte, hemoglobin, and total red blood cell measurements.
- Day 1 pre-dose, 3, 6, 12, and 16 hours
- Day 2 24 and 36 hours
- Day 3 Day 5
- Day 7, Day 10 Day 15 (pre-dose)
- Day 16, and Day 28 Day 1
- WinNonlin was also be used to calculate AUC(o_ ⁇ as t) (of the differences from the baseline) for reticulocyte, hemoglobin, and red blood cell data. Applicable statistical analyses (i.e., ANOVA, t-test) were conducted.
- FIG. 2 Also seen in Figure 2 is a sharp increase and subsequent decrease for EPREX following administration of the drug. The decrease is mitigated in all of the CMC formulations, demonstrative of the amount of systemic EPO released from the injection site of these formulations.
- Figures 3 and 4 demonstrate the change in Hemoglobin and red blood cell (RBC) versus time. Except for the CMC formulations containing 50mg/ml mannitol and
- Formulations EPREX 40,000 dose CMC: 5 40,000 IU EPO, 7% CMC, 20 mM Na Phosphate buffer, pH 7, 5 mg/ml Glycine (0.5%), 75 mMNaCl, 0.3% Tween 80.
- the CMC-5 formulation demonstrated superior pharmacokinetic properties to EPREX, characterized by a lower C max and a. longer T ⁇ /2 .. This formulation also demonstrated to have slightly better pharmacodynamic properties than EPREX.
- EPREX 80K 80,000 IU/mL dose
- test and control articles were administered by multiple subcutaneous injections to beagle dogs, one injection per three- week period.
- C max The maximum mean plasma concentrations (C max ) and their times of occurrence (T max ) of EPO were determined.
- terminal rate constants (k) were estimated by fitting a linear regression of log mean concentration against time using data points randomly distributed about a single straight line. Terminal half-lives were calculated as In2/k.
- the changes from baseline in the pharmacodynamic parameters (% reticulocytes, hemoglobin, total red blood cells) was calculated using the value on Day 1 as the baseline value.
- the AUC of the change in pharmacodynamic values from baseline was calculated using linear trapezoidal rule.
- the pharmacokinetics of CMC-6 demonstrated a lower C max and a lower T y 2 than EPREX control.
- the pharmacodynamics of CMC-6 demonstrated a superior change in reticulocyte production by Day 6, but similar pharmacodynamic properties to EPREX in all other measures.
- This study was designed to assess the pharmacokinetics and pharmacodynamics of the test articles in the male beagle dog administered via subcutaneous injection.
- Housing one room for the study, in an air-conditioned building: temperature: 19 to 25°C (target range) relative humidity: > 40 %, air changes: - minimum ten air changes per hour, lighting cycle: twelve hours light (artificial)/twelve hours dark.
- Caging animals housed singly in pens (1.44 m ).
- Diet pelleted complete commercial diet (Diet 125C1, UAR); analyzed for the absence of chemical and bacteriological contaminants.
- Quantity distributed 300 g/animal/day (food offered after dosing on treatment days and at approximately the same time of day on other study days).
- Contaminants no contaminants known to be present in the diet or water at levels which might interfere with achieving the objective of the study. Certificates of analysis for the diet and for the water will be maintained in the archives of the testing facility.
- Allocation to treatment group performed during the acclimatization period: random allocation procedure based on body weight classes.
- Animals were observed daily. During the treatment period, animals were examined before and at least once after dosing to detect any clinical signs or reaction to treatment. The injections sites were observed daily. A full clinical examination were performed before the initiation of treatment.
- Body Weight Individual weighing once weekly, starting two weeks before initiation of treatment.
- Plasma samples were obtained by centrifugation at approximately 3000 rpm for ten minutes and transferred to polypropylene tubes. The plasma samples were stored deep-frozen (approximately - 20°C) pending dispatch to the auxiliary Testing Facility 1.
- Body weight range (approximately) at initiation of study: 9 to 11 kg
- Animal Husbandry Housing one room for the study, in an air-conditioned building
- Air changes Minimum 10 air changes per hour
- Lighting cycle 12 hours light (artificially)/ 12 hours dark.
- Diet pelleted complete commercial diet (Diet 125C1, UAR), analyzed for the absence of chemical and bacteriological contaminants.
- Water mains drinking water, ad libitum, analyzed at least once a year for chemical contaminants and at least twice a year for bacterial contaminants.
- Contaminants no contaminants are known to be present in the diet or water at levels which might interfere with achieving the objective of the study. Certificates of analysis for the diet and for the water is maintained in the archives of the testing facility.
- Allocation to treatment group performed during the acclimatization period: random allocation procedure based on body weight classes.
- the dose level used for the second administration (day 15) is confirmed following the analysis of the first week's pharmacokinetic samples: the dose levels are defined by protocol amendment.
- Article A GCSF, Lot No. 14901-185, Concentration: 1.164 mg/ml formulated as described herein.
- Article B CMC-GCSF, Lot No. 15849-136-1, Concentration: 0.60 mg/ml formulated as described herein.
- Volume administered dependent on dosing regimen. Individual dose volumes are calculated on Days 1 and 15 to two decimal places according to the latest recorded body weight; these volumes are recorded in the study data. The syringes containing the dosing solution are weighed before and after administration in order to calculate the actual individual delivered dose.
- Animals are observed daily. During the treatment period, animals are examined before and at least once after dosing to detect any clinical signs or reaction to treatment. The injection sites are observed daily. A full clinical examination is performed before the initiation of treatment.
- Controls are run before and after each initial run of blood samples (repeat analysis not included). For each control batch, a mean and standard deviation are calculated per time- point for the entire in-house life span of each given batch used during the course of the study. The batch numbers are also recorded.
- the ADVIA, used to perform haematological determinations is operated in CBC/DIFF mode .in oxder to collect differential white blood cell data.
- Plasma samples are obtained by centrifugation at approximately 3000 rpm for ten minutes and transferred to polypropylene tubes. The plasma samples are stored in deep-frozen (approximately -20 degrees)
- the group mean values for all phamacodynbamic (haematology) parameters is plotted as graphs.
- the areas under the parameter-time curves (AUC(o- ⁇ st ) of the baseline adjusted parameter) are estimated by the linear trapezoidal rule Ortl531
- each individual parameter baseline is determined on a case-by-case basis using the value from either Day 1 or Day 3, the lower value of. the two setting the baseline.
- Arithmetic group mean and standard deviation values are calculated for each parameter and its respective (AU o-iast).
- T(max) are the observed values.
- the areas under plasma concentration-time curves (AU ), and their variances, are estimated by the linear trapezoidal rule according to Bailer (1988).
- terminal rate constants (k) are estimated by fitting a linear regression of log mean concentration against time using data points randomly distributed about a single straight line. Terminal half-lives are calculated as Ln2/k together with clearance (Cl + achieved dose/AUCt). Reference for this technique is AJ. Bailer, J. Pharmacokin. Biopharm., (1988) 16:303-309.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02780626A EP1441771B1 (en) | 2001-11-07 | 2002-10-25 | Aqueous sustained-release formulations of proteins |
SI200230773T SI1441771T1 (en) | 2001-11-07 | 2002-10-25 | Aqueous sustained-release formulations of proteins |
AU2002343666A AU2002343666B2 (en) | 2001-11-07 | 2002-10-25 | Aqueous sustained-release formulations of proteins |
MXPA04004367A MXPA04004367A (en) | 2001-11-07 | 2002-10-25 | Aqueous sustained-release formulations of proteins. |
BR0213992-8A BR0213992A (en) | 2001-11-07 | 2002-10-25 | Sustained Release Aqueous Protein Formulations |
DK02780626T DK1441771T3 (en) | 2001-11-07 | 2002-10-25 | Aqueous sustained release protein formulations |
CA002465890A CA2465890A1 (en) | 2001-11-07 | 2002-10-25 | Aqueous sustained-release formulations of proteins |
JP2003554227A JP2005514394A (en) | 2001-11-07 | 2002-10-25 | Aqueous sustained release formulation of protein |
DE60228864T DE60228864D1 (en) | 2001-11-07 | 2002-10-25 | AQUEOUS PROTEIN FORMULATION WITH DELAYED RELEASE |
HK04109347.7A HK1066468A1 (en) | 2001-11-07 | 2004-11-26 | Aqueous sustained-release formulations of proteins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/037,369 US6818613B2 (en) | 2001-11-07 | 2001-11-07 | Aqueous sustained-release formulations of proteins |
US10/037,369 | 2001-11-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003053471A1 true WO2003053471A1 (en) | 2003-07-03 |
Family
ID=21893975
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/036300 WO2003053471A1 (en) | 2001-11-07 | 2002-10-25 | Aqueous sustained-release formulations of proteins |
Country Status (20)
Country | Link |
---|---|
US (3) | US6818613B2 (en) |
EP (1) | EP1441771B1 (en) |
JP (1) | JP2005514394A (en) |
CN (1) | CN1612752A (en) |
AR (1) | AR037260A1 (en) |
AT (1) | ATE407701T1 (en) |
AU (1) | AU2002343666B2 (en) |
BR (1) | BR0213992A (en) |
CA (1) | CA2465890A1 (en) |
CY (1) | CY1110271T1 (en) |
DE (1) | DE60228864D1 (en) |
DK (1) | DK1441771T3 (en) |
ES (1) | ES2312633T3 (en) |
HK (1) | HK1066468A1 (en) |
MX (1) | MXPA04004367A (en) |
MY (1) | MY136952A (en) |
PT (1) | PT1441771E (en) |
SI (1) | SI1441771T1 (en) |
TW (1) | TWI332845B (en) |
WO (1) | WO2003053471A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006519210A (en) * | 2003-02-28 | 2006-08-24 | アレス トレーディング ソシエテ アノニム | Liquid formulation of tumor necrosis factor binding protein |
WO2009083203A2 (en) * | 2007-12-28 | 2009-07-09 | Heraeus Kulzer Gmbh | Topical application and formulation of erythropoietin for skin wound healing |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
US8940873B2 (en) | 2007-03-29 | 2015-01-27 | Abbvie Inc. | Crystalline anti-human IL-12 antibodies |
US10995130B2 (en) | 2011-07-01 | 2021-05-04 | Biogen Ma Inc. | Arginine-free TNFR:Fc-fusion polypeptide compositions and methods of use |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001087329A1 (en) * | 2000-05-15 | 2001-11-22 | F. Hoffmann-La Roche Ag | Liquid pharmaceutical composition containing an erythropoietin derivate |
US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
US6818613B2 (en) * | 2001-11-07 | 2004-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aqueous sustained-release formulations of proteins |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
US20040248784A1 (en) * | 2003-06-03 | 2004-12-09 | Marco Filicori | Unitary combinations of FSH and hCG |
EP1537876A1 (en) * | 2003-12-01 | 2005-06-08 | BioGeneriX AG | Erythropoietin solution formulation |
BRPI0506793A (en) * | 2004-02-20 | 2007-05-22 | Rinat Neuroscience Corp | Obesity or diabetes treatment methods using nt-4/5 |
US7772182B2 (en) * | 2004-08-05 | 2010-08-10 | Alza Corporation | Stable suspension formulations of erythropoietin receptor agonists |
KR101150242B1 (en) | 2004-10-27 | 2012-06-13 | 유니버시티 오브 덴버 | Adrenocorticotropic hormone analogs and related methods |
CU23432B6 (en) * | 2005-11-02 | 2009-10-16 | Ct Ingenieria Genetica Biotech | STABILIZED FORMULATIONS CONTAINING GAMMA AND ALFA INTERFERONS IN POTENTIAL PROPORTIONS |
US7935342B2 (en) * | 2006-02-02 | 2011-05-03 | Rinat Neuroscience Corp. | Methods for treating obesity by administering a trkB antagonist |
NL2000464C2 (en) * | 2006-02-02 | 2007-09-11 | Rinat Neuroscience Corp | Methods for treating unwanted weight loss or eating disorders by administering a TRKB agonist. |
KR20100040840A (en) | 2007-06-06 | 2010-04-21 | 도만티스 리미티드 | Polypeptides, antibody variable domains and antagonists |
EP2167115A2 (en) * | 2007-06-15 | 2010-03-31 | University Of Zurich | Treatment for alzheimer's disease |
US8795317B2 (en) * | 2009-07-08 | 2014-08-05 | Concentric Medical, Inc. | Embolic obstruction retrieval devices and methods |
US8357178B2 (en) * | 2009-07-08 | 2013-01-22 | Concentric Medical, Inc. | Vascular and bodily duct treatment devices and methods |
US8529596B2 (en) | 2009-07-08 | 2013-09-10 | Concentric Medical, Inc. | Vascular and bodily duct treatment devices and methods |
US20110009941A1 (en) * | 2009-07-08 | 2011-01-13 | Concentric Medical, Inc. | Vascular and bodily duct treatment devices and methods |
US9072537B2 (en) | 2009-07-08 | 2015-07-07 | Concentric Medical, Inc. | Vascular and bodily duct treatment devices and methods |
US8795345B2 (en) * | 2009-07-08 | 2014-08-05 | Concentric Medical, Inc. | Vascular and bodily duct treatment devices and methods |
US8357179B2 (en) * | 2009-07-08 | 2013-01-22 | Concentric Medical, Inc. | Vascular and bodily duct treatment devices and methods |
CA2815689C (en) | 2010-11-11 | 2016-11-22 | Abbvie Biotechnology Ltd. | Improved high concentration anti-tnf.alpha. antibody liquid formulations |
TW201842929A (en) * | 2017-05-03 | 2018-12-16 | 美商必治妥美雅史谷比公司 | Stable formulations of fibronectin based scaffold domain proteins that bind to myostatin |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1983001198A1 (en) * | 1981-10-08 | 1983-04-14 | Kurt Frimann Berg | Method and composition for treating a patient suffering from interferon-susceptible disorder |
WO1997007788A2 (en) * | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
WO1997028828A1 (en) * | 1996-02-09 | 1997-08-14 | Amgen Boulder Inc. | Composition comprising interleukin-1 inhibitor and controlled release polymer |
WO2000013710A2 (en) * | 1998-09-04 | 2000-03-16 | Scios Inc. | Hydrogel compositions for the controlled release administration of growth factors |
WO2000061169A1 (en) * | 1999-04-09 | 2000-10-19 | Ortho-Mcneil Pharmaceutical, Inc. | Pharmaceutical compositions of erythropoietin |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3865801A (en) * | 1973-06-15 | 1975-02-11 | Atomic Energy Commission | Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol |
EP0006227B1 (en) * | 1978-06-16 | 1984-12-27 | Kyowa Hakko Kogyo Co., Ltd | Antithrombotic pharmaceutical preparation containing 2,2'-dithiobis benzamide derivatives and new 2,2'-dithiobis benzamide derivatives |
JPH0686480B2 (en) * | 1983-02-21 | 1994-11-02 | 雪印乳業株式会社 | Monoclonal antibody for erythropoietin production |
ES8404783A1 (en) * | 1983-03-21 | 1984-05-16 | Prodes Sa | New 2-((2,6-dichlorophenyl)amine)phenylacetoxyacetyl derivatives, the process for preparing the same and their use in therapeutics. |
JPS604186A (en) * | 1983-06-21 | 1985-01-10 | Dai Ichi Seiyaku Co Ltd | Imidazoquinazoline compound |
DK173067B1 (en) | 1986-06-27 | 1999-12-13 | Univ Washington | Human erythropoietin gene, method of expression thereof in transfected cell lines, the transfected cell lines |
US4717717A (en) | 1986-11-05 | 1988-01-05 | Ethicon, Inc. | Stabilized compositions containing epidermal growth factor |
US5457093A (en) | 1987-09-18 | 1995-10-10 | Ethicon, Inc. | Gel formulations containing growth factors |
JP3249147B2 (en) * | 1990-06-01 | 2002-01-21 | キリン−アムジエン・インコーポレーテツド | Oral preparation containing bioactive protein |
DE4126983A1 (en) * | 1991-08-15 | 1993-02-18 | Boehringer Mannheim Gmbh | METHOD FOR THE PRODUCTION OF HUMAN-PROTEIN-CONTAINING, PRESERVED MEDICAMENTS FOR INFUSION OR INJECTION USE |
US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
US6153407A (en) | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
IL192290A0 (en) | 1993-08-17 | 2008-12-29 | Kirin Amgen Inc | Erythropoietin analogs |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5747446A (en) * | 1994-03-22 | 1998-05-05 | Beth Israel Deaconess Medical Center | Modified polypeptides with increased biological activity |
US5919758A (en) * | 1994-03-22 | 1999-07-06 | Beth Israel Deaconess Medical Center | Modified polypeptides with altered biological activity |
WO1996040074A2 (en) * | 1995-06-07 | 1996-12-19 | Alkermes Controlled Therapeutics, Inc. | Device for releasing aggregation-stabilized, biologically active agent |
CA2262994A1 (en) | 1996-08-02 | 1998-02-12 | Ortho-Mcneil Pharmaceutical, Inc. | Polypeptides having a single covalently bound n-terminal water-soluble polymer |
AU754619B2 (en) | 1997-07-23 | 2002-11-21 | Roche Diagnostics Gmbh | Production of erythropoietin by endogenous gene activation |
EP0902085B1 (en) | 1997-09-01 | 2003-12-03 | Aventis Pharma Deutschland GmbH | Recombinant human erythropoietin with advantageous glycosylation profile |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
ES2273497T3 (en) | 1998-06-15 | 2007-05-01 | Gtc Biotherapeutics, Inc. | FUSION PROTEIN OF THE SERIAL HUMAN ALBUMIN OF ERITROPOYETINA ANALOGA. |
US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
CO5160256A1 (en) | 1999-02-08 | 2002-05-30 | Zentaris Ag | SALTS OF PHARMACEUTICALLY ACTIVE PEPTIDES FOR SUSTAINED RELEASE AND PRODUCTION PROCESS |
CZ299516B6 (en) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof |
US6558702B2 (en) * | 2001-04-13 | 2003-05-06 | Alkermes Controlled Therapeutics, Inc. | Method of modifying the release profile of sustained release compositions |
US6818613B2 (en) * | 2001-11-07 | 2004-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aqueous sustained-release formulations of proteins |
-
2001
- 2001-11-07 US US10/037,369 patent/US6818613B2/en not_active Expired - Lifetime
-
2002
- 2002-10-25 AU AU2002343666A patent/AU2002343666B2/en not_active Ceased
- 2002-10-25 SI SI200230773T patent/SI1441771T1/en unknown
- 2002-10-25 DE DE60228864T patent/DE60228864D1/en not_active Expired - Lifetime
- 2002-10-25 MX MXPA04004367A patent/MXPA04004367A/en unknown
- 2002-10-25 CA CA002465890A patent/CA2465890A1/en not_active Abandoned
- 2002-10-25 BR BR0213992-8A patent/BR0213992A/en not_active IP Right Cessation
- 2002-10-25 CN CNA028268903A patent/CN1612752A/en active Pending
- 2002-10-25 AT AT02780626T patent/ATE407701T1/en active
- 2002-10-25 PT PT02780626T patent/PT1441771E/en unknown
- 2002-10-25 EP EP02780626A patent/EP1441771B1/en not_active Expired - Lifetime
- 2002-10-25 JP JP2003554227A patent/JP2005514394A/en not_active Ceased
- 2002-10-25 ES ES02780626T patent/ES2312633T3/en not_active Expired - Lifetime
- 2002-10-25 DK DK02780626T patent/DK1441771T3/en active
- 2002-10-25 WO PCT/US2002/036300 patent/WO2003053471A1/en active IP Right Grant
- 2002-11-06 TW TW091132632A patent/TWI332845B/en not_active IP Right Cessation
- 2002-11-06 AR ARP020104235A patent/AR037260A1/en unknown
- 2002-11-06 MY MYPI20024140A patent/MY136952A/en unknown
-
2003
- 2003-03-31 US US10/403,115 patent/US20030181361A1/en not_active Abandoned
-
2004
- 2004-08-18 US US10/920,803 patent/US7282480B2/en not_active Expired - Fee Related
- 2004-11-26 HK HK04109347.7A patent/HK1066468A1/en not_active IP Right Cessation
-
2008
- 2008-12-10 CY CY20081101432T patent/CY1110271T1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1983001198A1 (en) * | 1981-10-08 | 1983-04-14 | Kurt Frimann Berg | Method and composition for treating a patient suffering from interferon-susceptible disorder |
WO1997007788A2 (en) * | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
WO1997028828A1 (en) * | 1996-02-09 | 1997-08-14 | Amgen Boulder Inc. | Composition comprising interleukin-1 inhibitor and controlled release polymer |
WO2000013710A2 (en) * | 1998-09-04 | 2000-03-16 | Scios Inc. | Hydrogel compositions for the controlled release administration of growth factors |
WO2000061169A1 (en) * | 1999-04-09 | 2000-10-19 | Ortho-Mcneil Pharmaceutical, Inc. | Pharmaceutical compositions of erythropoietin |
Non-Patent Citations (2)
Title |
---|
CHEUNG W ET AL: "Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly.", EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol. 57, no. 5, August 2001 (2001-08-01), pages 411 - 418, XP002233399, ISSN: 0031-6970 * |
TROXEL TR ET AL: "Ovulation and reproductive hormones following steroid pretreatment, calf removal and GnRH in postpartum suckled beef cows", JOURNAL OF ANIMAL SCIENCE, vol. 51, no. 3, 1980, pages 652 - 659, XP008014542, ISSN: 0021-8812 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006519210A (en) * | 2003-02-28 | 2006-08-24 | アレス トレーディング ソシエテ アノニム | Liquid formulation of tumor necrosis factor binding protein |
US8940873B2 (en) | 2007-03-29 | 2015-01-27 | Abbvie Inc. | Crystalline anti-human IL-12 antibodies |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
US9085619B2 (en) | 2007-11-30 | 2015-07-21 | Abbvie Biotechnology Ltd. | Anti-TNF antibody formulations |
US11167030B2 (en) | 2007-11-30 | 2021-11-09 | Abbvie Biotechnology Ltd | Protein formulations and methods of making same |
US11191834B2 (en) | 2007-11-30 | 2021-12-07 | Abbvie Biotechnology Ltd | Protein formulations and methods of making same |
WO2009083203A2 (en) * | 2007-12-28 | 2009-07-09 | Heraeus Kulzer Gmbh | Topical application and formulation of erythropoietin for skin wound healing |
WO2009083203A3 (en) * | 2007-12-28 | 2010-02-18 | Heraeus Kulzer Gmbh | Topical application and formulation of erythropoietin for skin wound healing |
RU2465003C2 (en) * | 2007-12-28 | 2012-10-27 | Херойс Кульцер Гмбх | Local application and erythropoietin preparations for skin wound healing |
US9101586B2 (en) | 2007-12-28 | 2015-08-11 | Augustine Bader | Topical application and formulation of erythropoietin for skin wound healing |
US10995130B2 (en) | 2011-07-01 | 2021-05-04 | Biogen Ma Inc. | Arginine-free TNFR:Fc-fusion polypeptide compositions and methods of use |
US11834491B2 (en) | 2011-07-01 | 2023-12-05 | Biogen Ma Inc. | Arginine-free TNFR:FC-fusion polypeptide compositions |
Also Published As
Publication number | Publication date |
---|---|
US20030181361A1 (en) | 2003-09-25 |
US7282480B2 (en) | 2007-10-16 |
DK1441771T3 (en) | 2009-01-05 |
BR0213992A (en) | 2004-08-31 |
PT1441771E (en) | 2008-10-29 |
TWI332845B (en) | 2010-11-11 |
MY136952A (en) | 2008-12-31 |
US20030148938A1 (en) | 2003-08-07 |
CY1110271T1 (en) | 2015-01-14 |
US6818613B2 (en) | 2004-11-16 |
MXPA04004367A (en) | 2005-05-16 |
HK1066468A1 (en) | 2005-03-24 |
DE60228864D1 (en) | 2008-10-23 |
CA2465890A1 (en) | 2003-07-03 |
EP1441771A1 (en) | 2004-08-04 |
EP1441771B1 (en) | 2008-09-10 |
AU2002343666A1 (en) | 2003-07-09 |
AU2002343666B2 (en) | 2007-04-05 |
AR037260A1 (en) | 2004-11-03 |
ES2312633T3 (en) | 2009-03-01 |
SI1441771T1 (en) | 2009-02-28 |
TW200303215A (en) | 2003-09-01 |
ATE407701T1 (en) | 2008-09-15 |
JP2005514394A (en) | 2005-05-19 |
US20050164927A1 (en) | 2005-07-28 |
CN1612752A (en) | 2005-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6818613B2 (en) | Aqueous sustained-release formulations of proteins | |
Wang et al. | Sustained-release interleukin-2 following intramuscular injection in rats | |
JP2004513872A (en) | Injection medium for polymer-based formulations | |
AU2008243150B2 (en) | Formulation comprising bioactive agents and methods of using same | |
JP3479082B2 (en) | Thrombopoietin composition | |
AU2003251284B9 (en) | Stable pharmaceutical composition comprising erythropoietin | |
EP3125922B1 (en) | Liquid pharmaceutical composition of conjugated erythropoietin | |
AU2002368075B2 (en) | Stable pharmaceutical composition comprising erythropoietin | |
US20030211976A1 (en) | Polyamino acid-based particle insulin formulation | |
CA2387229A1 (en) | Biodegradable microparticles with novel erythropoietin stimulating protein | |
NZ546451A (en) | Erythropoietin solution formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2465890 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002343666 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/004367 Country of ref document: MX Ref document number: 2003554227 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002780626 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028268903 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002780626 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002343666 Country of ref document: AU |